首页> 外文期刊>The Journal of rheumatology >Measures of response in clinical trials of systemic sclerosis: the combined response index for systemic sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).
【24h】

Measures of response in clinical trials of systemic sclerosis: the combined response index for systemic sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).

机译:系统性硬化症临床试验中的反应测度:系统性硬化症的反应指数(CRISS)和与系统性硬化症相关的肺动脉高压的结果测度(EPOSS)。

获取原文
获取原文并翻译 | 示例
           

摘要

There have been steady efforts to develop a combined response index for systemic sclerosis (CRISS). A parallel and equally successful effort has been made by an Expert Panel on Outcome Measures in PAH related to Systemic Sclerosis (EPOSS) to measure effect in treatment of pulmonary arterial hypertension of systemic sclerosis (PAH-SSc). CRISS conducted a Delphi process combined with expert review to identify 11 candidate domains for inclusion in a core set of outcomes for SSc clinical trials: soluble biomarkers, cardiac, digital ulcers, gastrointestinal, global health, health related quality of life (HRQOL) and function, musculoskeletal, pulmonary, Raynaud's, renal, and skin. Tools within domains were also agreed upon. Concentrating on one aspect of disease, PAH, EPOSS also conducted a Delphi process and judged the following domains as the most appropriate for randomized controlled trials in PAH-SSc: lung vascular/pulmonary arterial pressure, cardiac function, exercise testing; severity of dyspnea, discontinuation of treatment; quality of life/activities of daily living; global state; and survival. Possible useful tools within each domain were also agreed on. Patient derived, physician derived, and objective measures of response will be included and combined with the idea that each reflects different aspects of PAH (EPOSS) and overall disease (CRISS) although this assumption may not prove true and can be separated if statistically and clinically valid to do so. In either case, prospective studies will require measurement of all domains, and tools are required and will be developed to define appropriate combined measures of response. CRISS and EPOSS are being developed through the OMERACT process. Through Delphi process and literature review significant progress has been made for both indices, and prospective data are being collected.
机译:一直在努力开发针对全身性硬化症的综合反应指数(CRISS)。与系统性硬化症相关的PAH结果测量专家小组(EPOSS)做出了平行且同样成功的努力,以评估对系统性硬化症的肺动脉高压的治疗效果(PAH-SSc)。 CRISS进行了Delphi程序,并进行了专家审查,以确定11个候选域纳入SSc临床试验的核心结果集:可溶性生物标志物,心脏,数字性溃疡,胃肠道,全球健康,与健康相关的生活质量(HRQOL)和功能,肌肉骨骼,肺,雷诺氏,肾和皮肤。领域内的工具也已达成共识。专注于疾病的一方面,PAH,EPOSS还进行了Delphi程序,并判断以下领域最适合用于PAH-SSc中的随机对照试验:肺血管/肺动脉压,心脏功能,运动测试;呼吸困难的严重程度,停止治疗;生活质量/日常生活活动;全球状态和生存。每个领域内可能有用的工具也已达成共识。将包括患者派生,医师派生以及客观的反应措施,并将其与每个都反映PAH(EPOSS)和整体疾病(CRISS)的不同方面的想法相结合,尽管这种假设可能无法证明是正确的,并且如果在统计学和临床​​上可以分开这样做是有效的。在这两种情况下,前瞻性研究都将需要对所有领域进行衡量,并且需要工具并将其开发以定义适当的组合应对措施。 CRISS和EPOSS是通过OMERACT流程开发的。通过Delphi过程和文献回顾,两个指数均取得了重大进展,并且正在收集预期数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号